United Therapeutics (UTHR) return on equity (ROE)

Return on equity · fiscal 2025
18.8%

United Therapeutics (UTHR) earned a return on equity of 18.8% in fiscal 2025 (the year ended December 31, 2025). That is 0.3 percentage points higher than the 18.5% of fiscal 2024. Figures as of 17 Nov 2026, 21:31 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
18.8%
Change on fiscal 2024
+0.3 pts
Highest on record
41.0%fiscal 2015
Lowest on record
-8.9%fiscal 2008
Fiscal years on record
132008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

United Therapeutics return on equity (ROE), in more detail

Across the 13 fiscal years on record (2008–2025), the highest was 41.0% in fiscal 2015 and the lowest -8.9% in fiscal 2008. The fiscal 2025 figure is higher than in 67% of the 12 earlier fiscal years on record, whose median is 15.8%.

History · 13 fiscal years

Return on equity by fiscal year

United Therapeutics return on equity (ROE), year by year

United Therapeutics (UTHR) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202518.8% 0.3 pts up
202418.5% 2.1 pts up
202316.5% 1.3 pts up
202215.2% 3.1 pts up
202112.0%—
2019-3.8% 24.9 pts down
201821.1% 1.2 pts up
201719.9% 18.7 pts down
201638.6% 2.5 pts down
201541.0%—
201012.0% 9.0 pts up
20093.0% 11.9 pts up
2008-8.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of United Therapeutics and comparable companies
CompanyReturn on equityFiscal year
STERIS STE10.9%2026
Insmed INSM-172.8%2025
United Therapeutics UTHR18.8%2025
Incyte INCY24.9%2025
Viatris VTRS-23.9%2025
Tenet Healthcare THC33.3%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on UTHR

United Therapeutics, figure by figure

United Therapeutics (UTHR) overview: price, valuation and scorecardAll health care companies by market value

United Therapeutics return on equity (ROE): questions and answers

What is United Therapeutics's return on equity?

United Therapeutics (UTHR) earned a return on equity of 18.8% in fiscal 2025 (the year ended December 31, 2025). That is 0.3 percentage points higher than the 18.5% of fiscal 2024.

Is United Therapeutics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 12 earlier fiscal years on record, whose median is 15.8%.

What are the highest and lowest return on equity figures on record for United Therapeutics?

Across the 13 fiscal years on record (2008–2025), the highest was 41.0% in fiscal 2015 and the lowest -8.9% in fiscal 2008.

How is United Therapeutics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “United Therapeutics (UTHR) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/UTHR/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.